News

A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...
Evernorth's findings, which were broken down by generation, were even more stark, demonstrating a 67.8 percent uptick in Ozempic and Wegovy use among Gen Z, or those currently between the ages of ...
Two recent studies, the first from the from the data firm Truveta and the second from Evernorth Research Institute, demonstrated significant upticks in teenagers taking Novo Nordisk's ...
Novo Nordisk, the maker of Ozempic and Wegovy, insists there’s no reason to panic. Slim-down shots might melt fat fast — but docs say teens should ditch the syringes and stick to sweat, not ...
Healthcare conglomerate CVS Health CVS formed its Health Services segment through a realignment tied to a new operating model adopted in early 2023. In its last reported quarter, the segment ...
CVS will also serve as the first retail pharmacy in NVO’s NovoCare pharmacy network, increasing Wegovy’s access at 9,000 community health locations.
Cigna Evernorth Services is laying off 62 workers in New Jersey, the insurer told the state in a WARN Act filing. One employee was laid off March 15, another on March 29 and seven more on April 12 ...
Evernorth acquired the 6.5 acre property on Kelly's Field Road in Hinesburg in 2015 from a private owner, who had already built Section 8 housing for seniors on the site.
Ozempic and Wegovy generated combined sales of DKK 50.1 billion in the first quarter of 2025, accounting for around 66% of the company’s total revenues. Novo Nordisk is a global market leader in ...
Wegovy is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults and children over 12 with obesity, defined as a body mass index (BMI) of 30 or higher, and ...
Based on the electronic health records of 1.3M people aged 12–17 years, health data firm Truveta found that there were 9.9 new Wegovy prescriptions per 100,000 in 2023, the first full year when ...